Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: justaninvestor who wrote (389)	6/12/1998 1:59:00 PM
From: eRM Solutions	Read Replies (2) \| Respond to of 5402

If anyone wants to know why AndrewH is here read the following. The quicker you people become immune to the tactics the quicker we can all make $$$. The time for thses people is quickly coming to an end. Just remember these ROACHS do not like the light of day. BEST ADVICE IS JUST IGNORE THEM, IMO. ragingbull.com

To: justaninvestor who wrote (389)	6/12/1998 2:06:00 PM
From: drdan	Respond to of 5402

Hi, everyone. Just got off the phone wth the fda, division of blood product evaluation. I spoke with a lady named Marcy who told me that drugs which are structurally and functionally related to an already apporved drug do not as a fact get quicker approval. However, the process theortically is sped up because FDA researchers would already have data from the previous testing to go along with the present testing. Now remember that this would only apply if the two drugs were functionally similar. I dont imagine that this info amounts to much until we can speak with Dr.Drees.